Apomorphine transdermal patch - Altea

Drug Profile

Apomorphine transdermal patch - Altea

Latest Information Update: 15 Nov 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Altea Therapeutics
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 12 Nov 2012 Nitto Denko acquires all assets of Altea Therapeutics
  • 09 Dec 2011 Discontinued - Phase-I for Parkinson's disease in USA (Transdermal)
  • 09 Dec 2011 Discontinued - Preclinical for Parkinson's disease in Japan (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top